701205-60-9

Usage

Chemical structure

A complex chemical compound with multiple functional groups and a heterocyclic indole ring.

Bromophenyl sulfonyl group

A functional group containing a bromine atom attached to a phenyl ring, which is connected to a sulfonyl group.

Methoxy group

An ether functional group consisting of an oxygen atom connected to a methyl group, which is attached to the indole ring.

Methylpiperazinylmethyl group

A functional group containing a piperazine ring with a methyl group attached to it, which is connected to the indole ring.

Indole ring

A heterocyclic aromatic ring system with a nitrogen atom in the ring, which is common in many bioactive compounds.

Potential pharmacological activity

The presence of the indole ring suggests that 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole may have potential pharmacological activity, although further research is needed to confirm this.

Chemical properties and reactivity

The sulfonyl and bromophenyl groups may confer specific chemical properties and reactivity to the compound, which could be useful in various applications.

Further research and analysis

To determine the exact uses and properties of this chemical, additional research and analysis would be necessary.

Structural motif

The indole ring is a common structural motif in many bioactive compounds, which may contribute to the potential pharmacological activity of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole.

Synthesis and purification

The synthesis and purification of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole would require specific chemical reactions and techniques, which would need to be optimized for large-scale production.

Upstream product

• 701205-15-4 5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole 
• 2905-25-1 o-bromobenzenesulfonyl chloride 
• 1006-94-6 5-methoxylindole 
• 109-01-3 1-methyl-piperazine 

Relevant academic research and scientific papers

Synthesis of carbon-11-labeled 5-HT6R antagonists as new candidate PET radioligands for imaging of Alzheimer's disease

Carbon-11-labeled serotonin (5-hydroxytryptamine) 6 receptor (5-HT6R) antagonists, 1-[(2-bromophenyl)sulfonyl]-5-[11C]methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole (O-[11C]2a) and 1-[(2-bromophenyl)sulfonyl]-5-metho

Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease

Optimization of a novel series of 3-(piperazinylmethyl) indole derivatives as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists resulted in identification of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (5al, SUVN-502) as a clinical candidate for potential treatment of cognitive disorders. It has high affinity at human 5-HT6R (Ki = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins. It has high selectivity over 5-HT2A receptor. It is orally bioavailable and brain penetrant with robust preclinical efficacy. The combination of 5al, donepezil, and memantine (triple combination) produces synergistic effects in extracellular levels of acetylcholine in the ventral hippocampus. Preclinical efficacy in triple combination and high selectivity over 5-HT2A receptors are the differentiating features which culminated in selection of 5al for further development. The Phase-1 evaluation of safety and pharmacokinetics has been completed, allowing for the initiation of a Phase-2 proof of concept study.

PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE

A process suitable for adoption to large scale manufacture of 1-[(2-bromophenyl-sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment

PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE

A process suitable for adoption to large scale manufacture of 1-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- 1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomat

TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY

The present invention relates to novel substituted tetracyclic 3-substituted indoles, represented by general formula (I), its stereoisomers, its radioisotopes, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically accep

N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM

The present invention relates to novel N-arylsulfonyl-3-substituted indole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their geometric forms, their N-oxides, their polymorphs, their pharmaceutically acceptable